— Know what they know.
Not Investment Advice

ABOS

Acumen Pharmaceuticals, Inc.
1W: -17.7% 1M: -1.1% 3M: +31.2% YTD: +33.2% 1Y: +111.8% 3Y: -34.5%
$2.67
-0.25 (-8.56%)
After Hours: $2.88 (+0.21, +7.87%)
NASDAQ · Healthcare · Biotechnology · $161.7M · Alpha Radar Buy · Power 59
Smart Money Score
Moderate 50
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$161.7M
52W Range0.855-3.6
Volume441,018
Avg Volume810,433
Beta0.21
Dividend
Analyst Ratings
7 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEODaniel J. O'Connell
Employees61
SectorHealthcare
IndustryBiotechnology
IPO Date2021-07-01
427 Park Street
Newton, VA 22902
US
434 297 1000
About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Recent Insider Trades

NameTypeSharesPriceDate
RA CAPITAL MANAGEMEN A-Award 6,060,606 $3.30 2026-03-16
Meisner Derek M M-Exempt 2,090 $1.85 2026-03-06
Meisner Derek M S-Sale 2,090 $3.26 2026-03-06
Meisner Derek M M-Exempt 2,090 $1.85 2026-03-06
Meisner Derek M M-Exempt 9,406 $1.85 2026-02-27

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms